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readiness
Bakani Mark Ncube, Admire Dube and Kim Ward* 
Abstract 
Insufficient access to quality, safe, efficacious and affordable medical products in Africa has posed a significant chal-
lenge to public health for decades. In part, this is attributed to weak or absent policies and regulatory systems, a lack 
of competent regulatory professionals in National Medicines Regulatory Authorities (NMRAs) and ineffective regional 
collaborations among NMRAs. In response to national regulatory challenges in Africa, a number of regional harmoni-
sation efforts were introduced through the African Medicines Regulatory Harmonisation (AMRH) initiative to, among 
others, expedite market authorisation of medical products and to facilitate the alignment of national legislative 
frameworks with the AU Model Law on Medical Products Regulation. The goals of the model law include to increase 
collaboration across countries and to facilitate the overall regional harmonisation process. The AMRH initiative is 
proposed to serve as the foundation for the establishment of the African Medicines Agency (AMA). The AMA will, as 
one of its mandates, coordinate the regional harmonisation systems that are enabled by AU Model Law domestica-
tion and implementation. In this paper, we review the key entities involved in regional and continental harmonisation 
of medicines regulation, the milestones achieved in establishing the AMA as well as the implementation targets and 
anticipated challenges related to the AU Model Law domestication and the AMA’s establishment. This review shows 
that implementation targets for the AU Model Law have not been fully met, and the AMA treaty has not been ratified 
by the minimum required number of countries for its establishment. In spite of the challenges, the AU Model Law and 
the AMA hold promise to address gaps and inconsistencies in national regulatory legislation as well as to ensure effec-
tive medicines regulation by galvanising technical support, regulatory expertise and resources at a continental level. 
Furthermore, this review provides recommendations for future research.
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Introduction
Africa is a continent with 55 countries and a population 
of about 1.2 billion people [1, 2]. The continent also has 
a high burden of communicable and non-communicable 
diseases which presents significant challenges for the 
health care system [1]. For instance, the World Health 
Organization (WHO) African Regional Office (AfRO) 
reports having 11% of the world’s population yet it bears 
a disproportionate burden of disease with 60% of people 
living with HIV/AIDS and more than 90% of the annual 
global malaria cases being in Africa [3]. Insufficient 
access to quality, safe, efficacious and affordable medi-
cal products in Africa has posed a significant challenge 
to public health for decades [4, 5]. Amongst low- and 
middle-income countries worldwide, the African region 
has the highest prevalence of poor-quality medicines 
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with an 18.7% prevalence of substandard and falsified 
medicines [6]. These challenges have largely been attrib-
uted to weak or absent medicines regulatory systems [4, 
7], which include unclear policies, as well as incomplete 
or incoherent legal and regulatory frameworks. In addi-
tion, challenges with high staff turnover and lack of com-
petent regulatory professionals in National Medicines 
Regulatory Authorities (NMRAs) together with poor 
regulatory infrastructure and ineffective regional collab-
orations among NMRAs exist [4, 5, 7–19]. All countries 
in Africa, with the exception of Sahrawi Republic, have 
an NMRA or an administrative unit conducting some or 
all expected NMRA functions [20]. However, the level 
of regulatory oversight on the continent has wide diver-
gence with some countries having robust and functional 
NMRAs, whereas other countries have regulatory sys-
tems that are virtually non-existent [5, 7, 13–15, 20, 21].
Due to regulatory legislation being created at the 
national level, neighbouring countries within Regional 
Economic Communities (RECs) can have considerably 
different procedures and systems for regulating as well as 
approving medical products [4, 14, 15]. Consequently, in 
cases where the NMRAs receive evidence dossiers that 
are identical, countries are under no obligation to adopt 
the regulatory decisions that have been made in another 
country [4, 15]. Applicants and manufacturers are obli-
gated to submit duplicative evidence dossiers to sev-
eral NMRAs for the registration of medical products in 
each country where the product is intended for market-
ing [4, 14, 15, 22]. Each submission of a dossier has time 
and cost implications with subsequent delays in patient 
access to medical products [4, 15]. The lack of regula-
tory policy harmonisation between countries is among 
the reasons for backlogs and NMRA staff duplicating 
efforts [4, 15]. Furthermore, in light of the globalisation 
of pharmaceutical manufacturing, it is very difficult for 
an NMRA to effectively regulate all medical products on 
its market [11, 23, 24]. In the present context of linked 
supply chains, one country is increasingly dependent on 
the quality and safety systems that are in place in another 
country [11, 23].
In some African countries, the availability of essential 
medical products is potentially delayed by disparities in 
legal provisions of key regulatory functions resulting in 
the need for regulatory convergence towards a common 
framework [20]. Therefore, in January 2016 the African 
Union (AU) Model Law on Medical Products Regulation 
was officially endorsed. This model law was developed 
and promoted by the New Partnership for Africa’s Devel-
opment (NEPAD) Agency, now referred to as the African 
Union Development Agency NEPAD (AUDA-NEPAD), 
to provide the legislative framework for good medicine 
regulation at a national level. In addition, the model law 
provides the national legislative framework for harmo-
nisation at the regional and sub-regional level, as well 
as to increase efficiencies in regional, sub-regional and 
national procedures. It is legislation meant to be domesti-
cated and implemented by AU Member States and RECs 
for regulatory systems harmonisation, to facilitate collab-
oration across countries, and to ensure that in countries 
involved in research and development medical products 
that hold promise are developed, tested, and scaled up 
for the improvement of health impact [4, 9, 14, 15, 25].
In response to national medicines regulatory chal-
lenges, the African Medicines Regulatory Harmonisation 
(AMRH) initiative was formalised in 2009 [5, 20, 25]. Its 
main aim is to create more effective, efficient and trans-
parent regulatory mechanisms in various African mar-
kets through collaborative regional mechanisms that, 
among others, achieve faster medical product approvals 
[18, 20, 25, 26]. The AMRH initiative intends to expand 
its scope of work gradually, commencing with generic 
medicine registration and moving towards oversight of 
vaccine clinical trials, pharmacovigilance, and the reg-
istration of New Chemical Entities (NCEs), medical 
devices and diagnostics [16, 19, 20]. The AMRH initiative 
also proposes to serve as the foundation for the establish-
ment of the African Medicines Agency (AMA) [1, 7, 11, 
19, 27–29].
This review maps the key entities, milestones, imple-
mentation targets and anticipated challenges related 
to the AU Model Law’s domestication and the AMA’s 
establishment. It also highlights the benefits and chal-
lenges of medicines regulatory harmonisation. We find 
that implementation targets for the AU Model Law have 
not been fully met, and the AMA treaty has not been 
ratified by the minimum required number of countries 
for its establishment. In spite of the challenges, the AU 
Model Law and the AMA hold promise to address gaps 
and inconsistencies in national regulatory legislation as 
well as ensure effective medicines regulation by galvanis-
ing technical support, regulatory expertise and resources 
at a continental level. Furthermore, this review provides 
recommendations for future research.
Regulatory systems and maturity level in Africa
All African countries, with the exception of Sahrawi 
Republic, have an NMRA or an administrative unit con-
ducting some or all expected NMRA functions [20]. 
However, only 7% have moderately developed capac-
ity and over 90% have minimal to no capacity [20]. In 
addition, African NMRAs have varying corporate pro-
files with some lawfully established as body corporate, 
whereas others operate as departments or units under 
their respective Ministry of Health [20, 26, 30, 31]. The 
NMRAs also have variable functionalities and they are 
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at different growth, expertise and maturity levels [20]. 
The ‘maturity level’ concept is incorporated in the Global 
Benchmarking Tool (GBT) used by WHO to objectively 
evaluate regulatory systems [32]. The GBT allows WHO 
and NMRAs to assess the regulatory system’s overall 
maturity on a scale of 1 (the existence of some regula-
tory system elements) to 4 (operation is at an advanced 
performance level and there is continuous improvement) 
[32]. Africa has no NMRA operating at maturity level 4. 
However, the NMRAs of Ghana and Tanzania operate at 
maturity level 3 [33]. All NMRAs on the continent even-
tually report to their Ministry of Health as the Minister 
has overall responsibility [20]. Regardless of the differ-
ences in organisational structures and remits, African 
NMRAs have for many years managed a diverse range 
of responsibilities and issues affecting medical product 
regulation, most often with limited resources [17]. Their 
main focus has been to ensure that the populations that 
they serve have access to a range of affordable essential 
medical products, which are usually generic medical 
products [17]. Therefore, NMRAs may have experience 
in the management of generics and have limited experi-
ence in NCE assessment, approval and registration [17].
Most African countries have medicines policies which 
support medical product regulation. A situational analy-
sis in WHO-AfRO revealed that 40 of the 46 countries 
surveyed have medical product legislation, although only 
15% of the NMRAs have a legal mandate to perform all 
five critical regulatory functions: marketing authorisa-
tion, pharmacovigilance, post-market surveillance, qual-
ity control, and clinical trials oversight [20]. Additionally, 
the regulatory oversight level has wide divergence with 
few member states having NMRAs that are robust and 
functional whereas other member states have regula-
tory systems that are virtually non-existent [5, 7, 13–15, 
20, 21]. The regulatory approaches and needs differ as a 
result of resource base, general development levels, eco-
nomic development, infrastructure, prevailing healthcare 
systems, research capacity and political commitment [7, 
8, 18]. Although WHO recommends NMRAs to regulate 
all types of medicines, of 26 African NMRAs included 
in a study, 65% have a mandate to control veterinary 
medicines, 69% have provisions for traditional/herbal 
medicine regulation, and 65% regulate a broad range of 
products including foods, pesticides, bottled water, cos-
metics and/or animal food supplements [20]. There is 
also a need for more robust pharmacovigilance systems 
as only 72% of countries in Sub-Saharan Africa (SSA) 
have quality control laboratories albeit at different devel-
opmental levels, and 63% are engaged in market surveil-
lance [20].
Over the past decade, the regulatory landscape in 
Africa has undergone considerable transformation [20]. 
However, there are existing and emerging medicine reg-
istration issues in Africa which include the regulation of 
biosimilars and vaccines, advancements in medical prod-
ucts, clinical trial regulation and the establishment of 
clinical trial registries, blood and blood product regula-
tion, and regulation of medical devices, especially diag-
nostic agents [7, 17, 23]. There are also reported delays 
of 4–7  years between first regulatory submission to a 
well-resourced NMRA and final approval in SSA [19, 20]. 
Some of the barriers that cause these delays are lengthy 
processes for medical products registration, general 
resource constraints, and failure to leverage regulatory 
review activities that have been carried out by stringent 
regulatory authorities [19]. Furthermore, the challenge of 
regulating medical products is exacerbated by the con-
tinent having more than 70% of medical products that 
are consumed being imported, which fuels illegal drug 
transactions as well as contributes to the consumption 
and circulation of substandard and falsified (SF) medical 
products [19].
The African Union Model Law on Medical Products 
Regulation
With the aim of ensuring the promotion of innova-
tion and access to new health technologies, the AUDA-
NEPAD and key stakeholders developed the AU Model 
Law on Medical Products Regulation, hereafter referred 
to as the AU Model Law [14, 15]. The goal of this non-
prescriptive model legislation is to streamline regulatory 
systems and facilitate the overall regional harmonisation 
process [4, 9, 14, 15, 19–21, 25]. The history of the AU 
Model Law is that the draft law was developed through 
the AMRH initiative platform and endorsed by the Pan 
African Parliament Committee on Health, Labour and 
Social Affairs [7, 21]. In November 2015, the AU tech-
nical committee on Justice and Legal Affairs approved 
the AU Model Law which is available for use as a start-
ing point for the establishment of regulatory bodies and 
providing support for legislation in AU Member States 
[9, 21]. In January 2016, the AU Model Law was then 
endorsed at the AU Summit in Addis Ababa, Ethiopia by 
the AU Heads of State and Government [10, 14, 20, 34]. 
Following endorsement, next steps taken were to engage 
with RECs, regional organisations (ROs), and member 
states to update and enact regional legal frameworks and 
national laws on the regulation of medical products [14, 
20, 34].
The objective of the AU Model Law is to increase col-
laboration across countries and to ensure that medical 
products that hold promise are developed, tested, and 
scaled up for the improvement of health impact [4, 9, 14, 
15, 25]. The AU Model Law also supports the AU’s desire 
to promote local pharmaceutical production, with the 
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goal of public health protection and economic growth 
[4], as well as supports continental efforts to advocate for, 
and catalyse access to novel medical products for patients 
in need [14, 19, 20]. Through the AU Model Law domes-
tication process, a country can adapt the AU Model Law 
so that it is consistent with its constitutional principles 
and legal system, as well as amend or repeal any incon-
sistent national laws in force [15, 19, 25, 35]. The AU 
Model Law is available in four different languages, i.e. 
English, French, Portuguese, and Arabic, and is intended 
to serve as a template for AU Member States to adopt 
best practices in medical products regulation into their 
national laws [14, 19, 20]. The key components of the AU 
Model Law are presented in Fig. 1.
For African countries without internationally compa-
rable laws, the implementation of the AU Model Law is 
expected to have an impact on the national regulatory 
system and the implementation benefits can be seen at 
the technical level as well as at the more general health 
systems level [34]. Regarding the broader health system, 
the AU Model Law implementation benefits include: (i) 
having national laws that are up to international stand-
ards, allowing the respective governments to catalyse 
access to innovative and lifesaving medical products for 
citizens [15, 34]; (ii) supporting access to health by ensur-
ing medical product availability; (iii) supporting, in the 
respective country, effective market control for medical 
products that are in circulation; and (iv) having legal pro-
visions at the national level that allow regional harmo-
nisation and international collaboration [34]. Through 
AU Model Law implementation, AU Member States 
strengthen national and regional regulatory systems as 
well as reduce SF medical product prevalence through 
the enforcement of a provision for SF medical product 
prohibition [19].
Country‑level adoption of the AU Model Law
At a national and regional level, implementation targets 
related to the AU Model Law are to have at least three 
regions adopting regional policies and legal frameworks 
for medical product regulation by 2020 [34], and at least 
25 countries domesticating the AU Model Law by 2020 
[14, 19, 34]. Currently, 17 countries have adopted or 
adapted the AU Model Law [36] and they include Bur-
kina Faso, Burundi, Ivory Coast, Lesotho, Mozambique, 
Namibia, Rwanda, Seychelles, The Gambia, the Kingdom 
of Eswatini, United Republic of Tanzania (Zanzibar), and 
Zimbabwe. These countries offer lessons and best prac-
tices that can be emulated when revising national medi-
cines regulatory systems using the AU Model Law as the 
reference document [10, 14, 19, 20, 34]. They offer exam-
ples of domesticating and implementing a version of the 





























































Fig. 1 Key components of the AU Model Law
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AU Model Law that best responds to a country’s respec-
tive needs in order to set up a streamlined regulatory 
system that ensures that medical products meet interna-
tional standards of quality, safety and efficacy [34]. Mem-
ber States are called to use the AU Model Law and bring 
the commitments made by their respective governments 
at the continental level to fruition [34].
For the successful implementation of the AU Model 
Law, RECs, ROs and member states are encouraged to 
carry out a combination of preliminary situational and 
needs assessments on the existent medicines regulatory 
system, including existing frameworks, in individual 
countries using the AU Model Law as the benchmark 
[14, 34]. Based on the gaps that are identified, a roadmap 
should be developed for AU Model Law implementa-
tion that clearly outlines the action plan to address the 
gaps, and if feasible, RECs should harmonise regulatory 
requirements for their member states [14, 34]. We note 
that there is a paucity of information on how many coun-
tries have laws deemed to be sufficient/comprehensive 
and already satisfy the AU Model Law requirements. 
Therefore, research needs to be carried out to address 
the foregoing as well as to assess countries pre- and post-
AU Model Law implementation. The AU Model Law and 
AMRH initiative efforts are intended to support coun-
tries to rectify some of the regulatory challenges that 
they have been grappling with for many years [15]. The 
long term goal of the AMRH initiative is to establish the 
African Medicines Agency, which will have the mandate 
of overseeing the registration of specific medical prod-
ucts and coordinating regional harmonisation systems in 
Africa [14, 37]. Therefore, the AU Model Law’s develop-
ment is interpreted within the context of these overarch-
ing efforts towards regulatory harmonisation in Africa 
[14].
Establishing the African Medicines Agency
In Africa, regulatory systems in some countries are bet-
ter than in others [14, 30, 31]. These regulatory capacity 
disparities are considered a basis for the establishment 
of a continental regulatory system [30, 31]. To effectively 
address some of the challenges that are being faced by 
African countries, AU Member States are establish-
ing the AMA. These challenges include implement-
ing agreed procedures and processes, coordinating 
regulatory practices across sub-regions, priority setting 
for medical products against select diseases, pharma-
ceutical manufacturing promotion and optimally using 
the NMRA’s limited resources [11, 30, 31]. The establish-
ment of AMA is based on AU Executive Council Deci-
sion EX.CL/Dec.857 (XXVI) of January 2015 [19, 38]. In 
addition, Africa has several donors and networks for reg-
ulators which aim to enhance the availability of medical 
products and serve as opportunities for improving regu-
latory convergence at a continental level. Therefore, these 
donors and networks could potentially benefit from the 
regulatory oversight which the AMA’s establishment 
would provide [11, 30, 31]. Moreover, the alignment of 
regulatory systems strengthening efforts, harmonisation 
initiatives and advocating for AMA’s establishment are 
important for optimising pharmaceutical markets as well 
as ensuring the sustainable supply of medical products 
for priority and neglected diseases [19]. Figure  2 shows 
the historical context of the African Medicines Agency.
The African Medicines Agency Treaty
The AMA is to be established through a treaty which 
takes into consideration key AU decisions, declarations 
and policy frameworks including the 55th Decision of the 
AU {Assembly/AU/Dec.55(IV)} taken during the 2005 
Abuja Summit and the 19th Ordinary Session Decision of 
the Assembly {Assembly AU/Dec.442(XIX)} [1, 4]. On 11 
February 2019, the AU Assembly, during their 32nd Ordi-
nary Session in Addis Ababa, Ethiopia, adopted the treaty 
for the establishment of the AMA [38–40]. The treaty 
was then unanimously adopted by the African Ministers 
of Health gathered at the 71st World Health Assembly in 
Geneva [24, 28]. The AMA was expected to be launched 
in 2018 [25, 30], with efforts being made to ensure that 
the agency capitalises on already existent mechanisms, 
experiences and technologies to work in an effective 
manner towards the accomplishment of its objectives 
[30]. It has been estimated that in the first 5 years, a total 
of US$100 million will be required to fund the AMA with 
portions of this amount funding human resource costs, 
infrastructure and operational costs [31]. The AU Mem-
ber States have also agreed to provide contributions in 
kind to the AMA by way of dedicating part of the time of 
their NMRA staff for the work of the Agency [11, 30, 31, 
38]. This is to ensure that the AMA has a small critical 
mass of competent staff to enable the work of the experts, 
and that of their respective committees [11, 30]. The pro-
posed structure of the AMA is illustrated in Fig. 3.
In the context of moving towards AMA’s establish-
ment, the AMA treaty must be signed and then rati-
fied. Ratification refers to the national procedure 
where the member state puts in place a law that allows 
for the implementation of the AMA treaty [41]. Afri-
can health leaders are currently adopting the treaty 
and on 12 June 2019, Rwanda became the first AU 
Member State to sign the treaty [1, 28, 40]. As of Sep-
tember 2020, there are 17 AU Member States that have 
signed the treaty: Algeria, Benin, Burkina Faso, Chad, 
Ghana, Guinea, Gabon, Madagascar, Mali, Morocco, 
Niger, Rwanda, Sahrawi Republic, Senegal, Sierra 
Leone, Seychelles, and Tunisia. Only Burkina Faso, 
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Ghana, Mali, Rwanda and Seychelles have ratified the 
treaty [42]. Literature shows that the lack of political 
commitment within countries is one factor that could 
impede the implementation of regional or continental 
decisions. Misconceptions, particularly at lower levels 
of integration, should therefore be resolved along with 
any differences in policy [11, 13]. Other known factors 
exist which may further influence the establishment 
and envisaged success of the AMA such as:
1. Language barriers: the AU has at least six official lan-
guages with some RECs having more than two offi-
cial languages;
2. The creation of the African Continental Free Trade 
Area (AfCFTA): progress in this regard will have an 
impact on AMA’s progress as the agency’s activities 
will be conducted within the context of regional/con-
tinental integration;
3. The functionality of Regional Centres of Regulatory 
Excellence (RCOREs): regulatory capacity at NMRAs 
can be built through the optimum use of the estab-
lished RCOREs;
4. Political and policy leadership to support efforts in 
harmonisation at the AU and RECs; and
5. Sustainable financing mechanisms [11].
The value proposition of the African Medicines Agency
Intended to be an organ of the AU that is legally man-
dated by member states, AMA aims to provide a plat-
form for the coordination and strengthening of ongoing 
medicines regulatory harmonisation initiatives across the 
continent [1, 11, 24, 30, 31, 43]. It plans to ensure optimal 
use of scarce resources by pooling expertise, capacities 
and strengthening existing networks. The AMA is also 
intended to offer guidance, in addition to complementing 
and enhancing the harmonisation efforts of RECs. This 
will theoretically contribute to enhanced accessibility of 
quality-assured and affordable medical products [1, 11, 
24, 27, 30, 31, 39, 43, 44].
AU Member States have recommended that the 
establishment of AMA be done in a stepwise approach 
that involves the AUC and RECs [30, 31]. Under the 
leadership of the AMA, efforts in regulatory systems 
strengthening and harmonisation initiatives can be bet-
ter coordinated. This may result in improved sovereign 
control and medical products regulation that allows AU 
Member States to provide protection for public health 
more efficiently and effectively, particularly against risks 
associated with SF medical product use [11, 27, 39, 40]. 
Furthermore, the AMA proposes to enable expedited 
approvals for medical products that meet the health 
2010
60th Session of the WHO Regional 
Commi
ee for Africa held in Malabo, 
Equatorial Guinea, recommended the 
establishment of the AMA.
2012
The report of AIDS Watch Africa Ac­on Commi
ee of Heads of 
State & Government led to an AU Assembly Declara­on 
{Assembly/AU/Decl.2 (XIX)} in which the Council decided that the 
AMRH Ini­a­ve shall serve as the founda­on for AMA’s 
establishment
2013
The 8th African Vaccine Regulatory Forum (AVAREF) held in 
Uganda & the 3rd African Medicines Regulatory Conference 
held in South Africa both discuss and support AMA’s 
establishment.
2014
1st African Ministers of Health mee­ng is 
jointly convened in Luanda, Angola by the 
AUC & WHO. Key milestones for AMA’s 
establishment are endorsed in response to 
declara­on {Assembly/AU/Decl.2 (XIX)}, & 
decisions of the WHO Regional Commi
ee 
for Africa
Fig. 2 The historical context of the African Medicines Agency
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needs of Africans, particularly for conditions that affect 
Africa disproportionately, while also fostering the com-
petitiveness of locally manufactured medical products 
[11, 27]. Ultimately, instead of having 54 NMRAs on the 
African continent, each with its own regulatory require-
ments, the AMA intends, among other goals, to result in 
streamlined regulatory processes in order to enable the 
timely evaluation and subsequent registration of medical 
products [11].
Vision and mission of the AMA
The AMA’s vision is to ensure that all Africans have 
access to quality-assured, safe, efficacious and affordable 
medical products, that meet internationally recognised 
standards, for priority diseases or conditions [11, 30, 31, 
39, 40]. At the continental level, AMA’s mission is:
1. To coordinate national and sub-regional medicines 
regulatory systems;
2. To conduct regulatory oversight of selected medical 
products including traditional medicines; and
3. To promote cooperation, harmonisation and the 
mutual recognition of regulatory decisions [11, 20, 
24, 30, 31, 39, 40, 44].
AMA proposes to work collaboratively with NMRAs, 
provide technical guidance, reduce duplicative efforts, 
and ensure cost-effective use of limited resources [20]. 
In order to achieve its mandate, the AMA also intends 
to work with technical partners such as WHO, the EMA 
and US Food and Drug Administration for relevance and 
participation on normative standards, technical coop-
























Strategic Oversight, Financial 
Performance 
Fig. 3 The proposed structure of the AMA. The proposed governance structure of AMA includes Member States, a Board with strong African 
government and technical representation, key stakeholders and a Secretariat led by the Head of AMA. AMA’s Board will be responsible for 
strategic oversight and direction, financial performance and accounts to the Member States through the AUC. The Secretariat will be responsible 
for operational performance, strategy/business plan implementation, as well as coordination/facilitation of medicines regulatory activities 
and harmonisation. The AMA’s structure intends to ensure the maintenance of a lean staff and the use of both internal staff and experts from 
participating NMRAs. The role of key staff will therefore be the coordination of AMA’s activities. The European Medicines Agency (EMA) and WHO 
PQTm have used similar approaches. The Head of AMA will be supported by a resource mobilisation team, an advocacy and partnership team, a 
legal services team and a technical capacity team [11]
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access to quality-assured medical products may result 
from an enhanced regulatory environment created by 
AMA [30]. The AMA, serving as a reference centre that 
has a coordination and stewardship function for the 
regulatory activities of AU Member States, intends to 
perform the following as part of its core activities: (i) 
marketing authorisation; (ii) joint assessments and GMP 
Inspections; (iii) market surveillance; (iv) safety monitor-
ing; (v) oversight of clinical trials; and (vi) coordination of 
quality control laboratory services [11, 27, 30, 31].
Medicines assessment
There is a dearth of information on the extent of the qual-
ity and safety of medical products in African countries 
as a result of inadequate regulatory and post-marketing 
surveillance systems [11]. Compared to medicines, the 
situation for medical devices and in  vitro diagnostics 
is postulated to be worse due to the relatively limited 
capacity to regulate these products [11]. Therefore, for 
functions such as GMP inspections of foreign manufac-
turers, reviewing complex medical products and multi-
country clinical trials, AMA and regional agencies can 
optimise available resources within RECs by harmonis-
ing technical requirements and work sharing activities, 
as well as coordinating technical support for AU Member 
States [11, 38, 39]. It is worth noting that AMA will not 
replace NMRAs or the sub-regional medicines regula-
tory authorities which will be established by RECs [11, 
19, 38, 39]. Instead, the AMA desires to complement the 
efforts of NMRAs, RECs and ROs intending to create a 
conducive environment for the pharmaceutical industry 
to develop through enhanced coordination of the various 
stakeholders involved in African regulatory harmonisa-
tion initiatives [19]. NMRAs will still assess the major-
ity of medical products, have their regulatory decision 
making roles and put in place market controls for their 
specific territories [11, 19]. As the AU does not have 
sweeping legal powers over the national jurisdictions of 
member states, decisions made at the continental level 
are not legally enforceable in AU Member States [11]. 
Table 1 shows the level of implementation of regulatory 
functions at the NMRA, regional and AMA level.
Developing regulatory science specialists
Building on the experiences and strengths of the RCORE 
model, AMA intends to be an agency focused on devel-
oping regulatory science specialists [11, 24]. An RCORE 
is an institution, or partnership of institutions, with spe-
cific expertise in regulatory science as well as proven 
capacity and capabilities in the training or delivery of ser-
vices in at least one of the categories of regulatory and 
managerial functions that have been identified [19, 45]. 
Since 2014, the AMRH initiative has spearheaded the 
designation of 11 RCOREs that specialise in 8 regula-
tory functions, strengthening the development of regula-
tory capacity by leveraging existing academic, scientific/
research and regulatory institutions [10, 19, 20, 25, 45]. 
These RCOREs are specialised in pharmacovigilance, 
training in core regulatory functions, quality assurance 
and quality control, medicines registration and evalua-
tion, licensing of the manufacture, import, export, and 
distribution of medical products, inspection and surveil-
lance, and clinical trials oversight [19, 25, 45].
AMA intends to offer regulatory guidance on particular 
issues that are problematic for which technical capacity 
and expertise are limited at the national or regional level 
[11, 24, 39, 44]. In addition, by providing recommenda-
tions that AU Member States can use as a basis for their 
own regulatory decision making, AMA potentially builds 
on the strengthened capacity of medical product/health 
technology regulation in Africa [1, 38]. Some countries 
in Africa have not fully exploited the Trade-Related 
Aspects of Intellectual Property Rights (TRIPS) flexibili-
ties and this has been attributed to the technocrats who 
are tasked with dealing with Intellectual Property Rights 
(IPR) and access to medicines having generally limited 
Table 1 Level of implementation of regulatory functions 
at national, regional and continental level [11]
a  In some RECs, centralised registration may not be feasible as it is dependent 
on specific regional contexts. In addition, centralised registration will only be for 
selected products for which centralised registrations would offer a comparative 
advantage
b  The majority of NMRAs do not have the resource capacity to perform GMP 
inspections. Therefore, this function can ideally be done at both the national and 
regional level, though NMRAs have the final approval
c  In African countries, GMP inspections of API manufacturers, biologics 
and vaccines is virtually non-existent. Therefore, this function can ideally be 
coordinated and conducted at the continental level, though NMRAs have the 
final approval
d  Regional agencies and the AMA have the role of coordinating and facilitating 
information exchange at national, regional and continental level, particularly for 
SF medical products
e  Review and/or coordination of regulatory oversight of multi-country clinical 
trials
f  Regulatory guidance and/or coordination of regulatory oversight of clinical 
trials for investigative and innovative therapies (e.g. for pandemics such as Ebola 
and COVID-19)
Regulatory function NMRA Regional 
harmonisation
AMA
Registration of medical products X Xa NA
GMP inspection of manufacturers X Xb Xc
Inspection of supply chain (import-
ers, wholesalers, retailers)
X – –
Post-marketing surveillance X Xd Xd
Pharmacovigilance X – –
Regulation of clinical trials X Xe Xf
Quality control X – –
Medicine information X – –
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knowledge on the subject area. There are also capacity 
constraints that include weak legal/regulatory frame-
works and weak administrative capacity [13]. Therefore, 
having harmonised medicine registrations can assist the 
AU, through AMA, to effectively use TRIPS flexibilities 
for the production and import of generic medical prod-
ucts that are protected by patents in one or more African 
countries [43].
Medicines regulatory harmonisation in Africa
The role of regional economic communities in regulatory 
harmonisation
Regulatory harmonisation refers to the process of 
NMRAs aligning technical requirements for the devel-
opment and marketing of medical products [46]. In 
Africa, there are 8 RECs: Arab Maghreb Union (UMA); 
Common Market for Eastern and Southern Africa 
(COMESA); Community of Sahel-Saharan States (CEN-
SAD); East African Community (EAC); Economic Com-
munity of Central African States (ECCAS); Economic 
Community of West African States (ECOWAS); Inter-
governmental Authority on Development (IGAD); and 
the Southern African Development Community (SADC) 
[47]. Within the framework of the Pharmaceutical Manu-
facturing Plan for Africa (PMPA), the AMRH initiative 
has been implemented, in collaboration with WHO and 
partners, with the intention of supporting the strength-
ening of medical product regulatory systems in these 
RECs and member states [7, 10, 11, 16, 38, 43]. The part-
nership has resulted in RECs and regional health organi-
sations, which have been supported to serve as regional 
information sharing platforms, benefitting from regula-
tory requirements, standards, systems, legislation and 
practices that are harmonised [10, 11, 26]. The intention 
of the work done by RECs is to be a stepping stone for the 
harmonisation of activities in Africa [11].
Launched on 30 March 2012 [21], the EAC medicines 
regulatory harmonisation (MRH) project was the first 
successful regional group of the AMRH initiative [9] and 
it signalled the beginning of the implementation phase 
of the initiative across Africa [5, 19]. In 2015, the SADC 
MRH project was launched and it absorbed the ZaZi-
BoNa collaborative medicines registration initiative [19, 
36]. In the same year, the MRH programme for the West 
African region was launched in Accra, Ghana, focus-
ing on the development of national and regional GMP 
roadmaps [19, 25, 29]. In addition, the Organization of 
Coordination for the Fight Against Endemic Diseases in 
Central Africa (OCEAC) became involved in the AMRH 
initiative in July 2015 [29]. In April 2016, the IGAD mem-
ber states signed the Khartoum Declaration to Call for 
Action towards medicines regulatory collaboration and 
harmonisation programme implementation [19, 25]. 
Through the RECs, the AMRH initiative has established 
a regional platform for medical products and health tech-
nologies’ regulation which can be utilised for the build-
ing of trust, confidence, ownership as well as alignment 
especially for countries that are in the process of build-
ing medicines regulatory systems [10, 11]. The RECs have 
also supported medicines registration harmonisation by 
creating common pharmaceutical policies and opera-
tional plans backed by high-level political commitments 
and mandates [16, 18].
Challenges encountered in medicines regulatory 
harmonisation
Regulatory harmonisation in Africa is a challenge as 
a result of the wide array of regulatory environments 
and capacities [13]. Countries have different sovereign 
approaches to their legal and regulatory frameworks 
based on their own sociocultural values, as well as his-
torical and political landscapes [48]. This is one of the 
aspects that the AU Model Law can assist in after it has 
been adopted and implemented by the countries. In addi-
tion, regulatory divergence across borders can be a result 
of differences in the degree of acceptable risks and ben-
efits, disease burden, vulnerable populations, and costs 
[48]. Harmonisation is also made more challenging by 
gaps in the development of a unified regulatory science 
body and the availability of a competent regulatory work-
force [48]. In order for medical products regulation to be 
effective and yield the envisaged benefits, all aspects of 
regulation must be addressed [8], and regulators should 
adapt medicines regulatory harmonisation activities 
based on local circumstances [9]. It is also important for 
medicines regulatory harmonisation to take into consid-
eration the different commercial, regulatory and health-
care interests [7].
Drawing lessons from the SADC region, potential 
barriers to harmonisation are related to differences 
in organisational structures of the NMRAs, legislative 
and regulatory provisions, and guidance documents 
[9]. Another regulatory harmonisation challenge is 
having differences in risk–benefit decisions and inter-
pretation of legislation used by NMRAs for regulatory 
and product approvals [9]. For instance, the AU Model 
Law is being interpreted, domesticated and imple-
mented differently according to the local context and 
needs [9]. Even in situations where the same legal and 
scientific frameworks are used, NMRAs are going to 
have different priorities in terms of risks and benefits 
during medical product regulation [9]. Moreover, the 
fact that the final decision on marketing authorisation, 
after completion of the product’s technical assess-
ment, is still the prerogative of each NMRA is in itself 
a harmonisation challenge [9, 36]. Other challenges 
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encountered by countries in the SADC region’s ZaZi-
BoNa initiative include long registration review times 
owing to increased applications, backlogs, inadequate 
numbers of assessors, a lack of competency in the 
assessment of certain products such as biologicals and 
biosimilars, as well as a lack of clarity in country-level 
ZaZiBoNa processes [36].
Like the SADC region, the EAC region has no license 
that is valid for use in all its member states and the dif-
ferent NMRAs have the sole responsibility of granting 
marketing authorisations [5]. The EAC member states 
have also implemented higher levels of quality con-
trol in their harmonisation initiatives [5]. Their joint 
assessments require bioequivalence studies, whereas 
applications for marketing authorisation through 
national marketing authorisation pathways tend to 
waive such requirements [5]. In addition, some EAC 
NMRAs refuse to accept a joint decision [5], and this 
might be due to the economic model of NMRAs [9]. 
NMRAs obtain a significant portion of their funds 
from conducting GMP assessments, dossier reviews 
and other regulatory functions [5]. Through harmoni-
sation and central registrations, this source of income 
would be lost. Regardless of funding sources, a recur-
ring theme in regulatory harmonisation is that sustain-
able financing is a major barrier [9].
Garnering support for regulatory harmonisation is 
riddled with challenges [49], and although these chal-
lenges exist, regional harmonisation is possible and 
is occurring. In the EAC and SADC regions, NMRAs 
have jointly assessed dossiers through collaborative 
regulatory procedures (CRP) [20]. The NMRAs in 
these RECs have also conducted joint GMP inspec-
tions to enable faster product marketing authorisation 
[20]. In the EAC region, CRP work has resulted in a 
40–60% reduction in medicine approval timelines for 
a number of branded medicines [20]. Additionally, the 
SADC region’s ZaZiBoNa initiative has demonstrated 
that work sharing can successfully occur due to lead-
ership commitment, consistency and ownership [36]. 
Through ZaZiBoNa: medicine registration has become 
faster than it would if NMRAs worked independently, 
maximum output has resulted from sharing limited 
resources, and NMRAs have benefitted from capac-
ity building [36]. Therefore, the AMA can capitalise 
on these already existing harmonisation initiatives to 
work in an effective manner towards the accomplish-
ment of its objectives [30]. Moreover, the AMA can 
potentially overcome these harmonisation challenges 
and facilitate harmonisation by galvanising technical 
support, regulatory expertise and resources at a scale 
that neither the national nor regional initiatives can 
match [11].
Outlook and recommendations for the future
This article reviewed the AU Model Law and found that 
its aims include to facilitate the overall regional harmo-
nisation process and increase collaboration across coun-
tries. In addition, the article reviewed the AMA, which is 
being established by treaty to effectively address some of 
the challenges that are being faced by African countries, 
and reports that the AMRH initiative serves as the foun-
dation for its establishment. This review also shows that 
implementation targets for the AU Model Law have not 
been fully met, and the AMA treaty has not been rati-
fied by the minimum required number of countries for 
its establishment. The noted challenges related to regu-
latory harmonisation include countries having different 
sovereign approaches to their legal and regulatory frame-
works, regulatory divergence across borders, inadequate 
financial resources, gaps in the development of a unified 
regulatory science body and the lack of a competent reg-
ulatory workforce. Against this backdrop, we recommend 
the following:
 i. An assessment of the current status of imple-
mentation of the AU Model Law by AU Member 
States as it may provide a foundation for identify-
ing the existent gaps and opportunities for improv-
ing medical product/health technology regulation, 
public health protection and promotion, and phar-
maceutical industry advancement on the continent.
 ii. An examination of the enabling factors and chal-
lenges encountered in domesticating and imple-
menting the AU Model Law in AU Member States.
 iii. An analysis of the enabling factors and barriers 
encountered by AU Member States in signing and/
or ratifying the treaty for AMA’s establishment, 
with lessons also being drawn from Burkina Faso, 
Ghana, Mali, Rwanda and Seychelles’ experiences 
of treaty ratification.
 iv. A comparative study between the AMA initiative 
and other continental initiatives in order to draw 
lessons from their implementation and find areas 
of applicability to Africa.
 v. An investigation of African NMRAs’ expectations 
of the AMA, perceptions of their contributions 
to/in the AMA, and the perceived benefits of the 
AMA to their respective countries.
Conclusions
Regulatory harmonisation offers several benefits to the 
various pharmaceutical stakeholders in Africa, including 
industry and patients. However, the effective regulation 
of medicines that guarantees public health protection is 
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a complex undertaking, needing the application of robust 
medical, scientific and technical competency within the 
context of an appropriate legal framework. Therefore, the 
AU Model Law and the AMA hold promise to address 
gaps and inconsistencies in national regulatory legisla-
tion as well as to ensure effective medicines regulation by 
galvanising technical support, regulatory expertise and 
resources at a continental level.
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